What is the 13F Pro Quality Score for ELTX?

13F Pro ranks Elicio Therapeutics, Inc. (ELTX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ELTX's current score at https://13fpro.ai/research/ELTX (free sign-up required for the full ranking).

Where does 13F Pro source ELTX data?

All Elicio Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Elicio Therapeutics, Inc. files with the SEC under CIK 1601485. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ELTX in?

Elicio Therapeutics, Inc. (ELTX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ELTX research updated on 13F Pro?

ELTX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Elicio Therapeutics, Inc.(ELTX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1601485 ELTX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $28.3M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ELTX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Elicio Therapeutics, Inc. (ELTX), a Healthcare sector company. ELTX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $28.3m in revenue. Based on the latest XBRL financial filings (Q1 2026), Elicio Therapeutics, Inc. reports net income of $-11.8M, free cash flow of $-11.6M. Top institutional holders of ELTX by reported 13-F value include Knoll Capital Management,, VANGUARD CAPITAL MANAGEMENT, SUSQUEHANNA INTERNATIONAL GROUP, LLP, based on the most recent SEC filings. ELTX trades on the Nasdaq exchange and files with the SEC under CIK 1601485. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ELTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Elicio Therapeutics, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-11.8M

Free Cash Flow

Q1 2026

$-11.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2023

FY20 $2.9MFY21 $28.3MFY22 $2.3MFY23 —

Net Income

-24.8% YoY

$-35.2MFY 2023

FY20 $-80.1MFY21 $-54.6MFY22 $-28.2MFY23 $-35.2M

Operating Income

-50.6% YoY

$-35.7MFY 2023

FY20 $-55.3MFY21 $-39.3MFY22 $-23.7MFY23 $-35.7M

EPS (Diluted)

+92.2% YoY

$-6.96FY 2023

FY20 $-5.43FY21 $-1.93FY22 $-89.27FY23 $-6.96

Total Assets

+19.8% YoY

$27.1MFY 2023

FY20 $47.3MFY21 $96.5MFY22 $22.7MFY23 $27.1M

Total Debt

—FY 2023

FY20 $635.0KFY21 $0.00FY22 —FY23 —

Op. Cash Flow

-47.4% YoY

$-32.7MFY 2023

FY20 $-22.9MFY21 $-52.6MFY22 $-22.2MFY23 $-32.7M

Metric	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	—	$2.3M -91.9%	$28.3M +883.1%	$2.9M
Net Income	$-35.2M -24.8%	$-28.2M +48.3%	$-54.6M +31.9%	$-80.1M
Operating Income	$-35.7M -50.6%	$-23.7M +39.6%	$-39.3M +28.9%	$-55.3M
EPS (Diluted)	$-6.96 +92.2%	$-89.27 -4525.4%	$-1.93 +64.5%	$-5.43
Total Assets	$27.1M +19.8%	$22.7M -76.5%	$96.5M +103.8%	$47.3M
Total Debt	—	—	$0.00 -100.0%	$635.0K
Operating Cash Flow	$-32.7M -47.4%	$-22.2M +57.9%	$-52.6M -130.0%	$-22.9M

AI Insight: ELTX Financial Trends

Elicio Therapeutics burns cash every quarter with zero revenue and equity turned negative in Q1 2026, signaling mounting balance sheet stress.

• No revenue recorded across all eight quarters — company remains entirely pre-commercial with no top-line contribution.

• Equity deteriorated from $9M in Q1 2025 to $-1M in Q1 2026, marking a full reversal into negative book value.

• Operating cash outflow worsened to $-12M in Q1 2026, the largest single-quarter burn in the observed period.

⚠ Equity turned negative in Q1 2026 — with $9M debt and no revenue, liquidity runway is the critical near-term risk.

⚠ Op losses briefly narrowed to $-8M in Q3 2025 then re-widened to $-11M in Q1 2026 — cost trajectory is unstable.

AI Insight: ELTX Ratio Trends

Data is almost entirely unavailable for ELTX — only D/E across three quarters can be assessed, showing volatile leverage.

• D/E ratio available for only three quarters: 5.09 in Q2 2025, 2.55 in Q3 2025, and 6.11 in Q4 2025 — highly volatile.

• No OpMargin, NPM, ROE, ROA, or ROIC data is available across any reported period, limiting fundamental analysis entirely.

⚠ D/E spiked to 6.11 in Q4 2025 after falling to 2.55 in Q3 2025 — leverage instability warrants close monitoring.

⚠ Absence of profitability metrics across all periods suggests ongoing pre-revenue or early-stage status with limited financial visibility.

Get alerted when ELTX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Elicio Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ELTX

Knoll Capital Management, LLC
$6.7M630,915 sh
VANGUARD CAPITAL MANAGEMENT LLC
$5.5M518,638 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$2.8M257,900 sh
BALYASNY ASSET MANAGEMENT L.P.
$2.6M244,814 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.4M135,164 sh
RENAISSANCE TECHNOLOGIES LLC
$1.3M121,631 sh
JANE STREET GROUP, LLC
$1.1M102,000 sh
MILLENNIUM MANAGEMENT LLC
$991.6K92,762 sh
MARSHALL WACE, LLP
$796.5K74,512 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$756.9K70,804 sh

Fund	Value	Shares
Knoll Capital Management, LLC	$6.7M	630,915
VANGUARD CAPITAL MANAGEMENT LLC	$5.5M	518,638
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$2.8M	257,900
BALYASNY ASSET MANAGEMENT L.P.	$2.6M	244,814
GEODE CAPITAL MANAGEMENT, LLC	$1.4M	135,164
RENAISSANCE TECHNOLOGIES LLC	$1.3M	121,631
JANE STREET GROUP, LLC	$1.1M	102,000
MILLENNIUM MANAGEMENT LLC	$991.6K	92,762
MARSHALL WACE, LLP	$796.5K	74,512
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$756.9K	70,804

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ELTX on your watchlist

Track score changes the day Elicio Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ELTX a good stock to buy?

13F Pro's AI-powered analysis of Elicio Therapeutics, Inc. (ELTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ELTX are available on the ELTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ELTX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ELTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Elicio Therapeutics, Inc.'s investment landscape.